Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64453 | 0.85 | HRH3 (0.54) | KMT2AALDH1A1MAPK1MAPTHDAC3 | |
| SCHEMBL27412908 | 0.80 | LMNA (0.39) | MEN1KMT2AGAAALDH1A1LMNA | |
| SCHEMBL31198823 | 0.80 | ALDH1A1 (0.43) | MEN1KMT2AGAAALDH1A1LMNA | |
| SCHEMBL28544347 | 0.80 | HRH4 (0.48) | MEN1KMT2AMAPK10GAASLC2A1 | |
| SCHEMBL22159239 | 0.80 | HDAC3 (0.51) | MEN1KMT2AGAAALDH1A1LMNA | |
| SCHEMBL63616 | 0.80 | HDAC3 (0.54) | MEN1KMT2AGAAALDH1A1LMNA | |
| SCHEMBL5324137 | 0.79 | CYP2C9 (0.62) | MEN1KMT2AGAAALDH1A1LMNA | |
| SCHEMBL28314039 | 0.79 | HDAC3 (0.53) | MEN1KMT2AGAAALDH1A1LMNA | |
| SCHEMBL732967 | 0.78 | HDAC3 (0.58) | MEN1KMT2AMAPTHDAC3HDAC2 | |
| Ethylene SCHEMBL29031111 | 0.77 | HDAC3 (0.52) | MEN1KMT2AGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925357-B | Acylhydrazone compound, pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2023-06-06 | — | — | CN | disclosed |
| CN-111925357-A | Acylhydrazone compound, pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2020-11-13 | — | — | CN | disclosed |
| EP-3023426-A1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | Critical Outcome Technologies, Inc. (CA) | 2016-05-25 | — | — | EP | disclosed |
| US-9284275-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| EP-2318406-B1 | THIOSEMICARBAZONE INHIBITOR COMPOUNDS AND CANCER TREATMENT METHODS | CRITICAL OUTCOME TECHNOLOGIES INC (CA) | 2016-01-27 | — | — | EP | disclosed |
| US-8822475-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2014-09-02 | — | — | US | disclosed |
| US-8822475-B2 | Compounds and method for treatment of cancer | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2014-09-02 | — | — | US | disclosed |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2014-03-13 | — | — | US | disclosed |
| US-8580792-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2013-11-12 | — | — | US | disclosed |
| US-20120077820-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-29 | — | — | US | disclosed |
| US-8138191-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-8138191-B2 | Inhibitor compounds and cancer treatment methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2012-03-20 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2011-11-17 | — | — | US | disclosed |
| US-8034815-B2 | Imidazol-1-yl-(4-pyridin-2-yl-piperazin-1-yl)-methanethione; Critical Outcome Technologies' Iead compound (COTI); kinase inhibitor; anticarcinogenic agent; especially small cell lung cancer; cervical, ovarian, skin, prostate, breast, colorectal, head, neck, or kidney cancer, sarcoma, leukemia | CRITICAL OUTCOME TECHNOLOGIES, INC. (CA) | 2011-10-11 | — | — | US | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | CRITICAL OUTCOME TECHNOLOGIES INC. (CA) | 2010-01-21 | — | — | US | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | 6441513 CANADA INC. (CA) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171744-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | SLC6A6, SLCO1B3, SLC5A1 | MEN1 1113/4885KMT2A 2953/4885MAPK10 4459/4885 |
| US-20110281887-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | TBCA, SLC6A6, SLC5A1 | MEN1 1159/4885KMT2A 2822/4885MAPK10 4459/4885 |
| US-20120077820-A1 | COMPOUNDS AND METHOD FOR TREATMENT OF CANCER | TBCA, SLC6A6, SLC5A1 | MEN1 1159/4885KMT2A 2822/4885MAPK10 4459/4885 |
| US-20100015140-A1 | Inhibitor Compounds and Cancer Treatment Methods | MTOR, RICTOR, RPTOR | MEN1 2921/4885KMT2A 2414/4885MAPK10 404/4885 |
| US-20140072555-A1 | Inhibitor Compounds and Cancer Treatment Methods | MTOR, RICTOR, RPTOR | MEN1 2921/4885KMT2A 2414/4885MAPK10 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.